Developmental Delay, Treatment-Resistant Psychosis, and Early-Onset Dementia in a Man With 22q11 Deletion Syndrome and Huntington’s Disease

2018/05/01 by Martilias S. Farrell, Martilias Farrell, Maya Lichtenstein +14 · 7 citations
Biochemistry, Genetics and Molecular Biology · #Congenital heart defects research #Genetics and Neurodevelopmental Disorders #Genomic variations and chromosomal abnormalities

paper · pdf · doi:10.1176/appi.ajp.2017.17060638

Cited by

• Obstacles, Opportunities, and Ethical Considerations for Genomic Investigations of Individuals Continuously Hospitalized with Treatment-resistant Schizophrenia
• Integrating Genomics into Psychiatric Practice: Ethical and Legal Challenges for Clinicians. [europepmc]
• The genomics of major psychiatric disorders in a large pedigree from Northern Sweden. [europepmc]
• Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene. [europepmc]
• Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review. [europepmc]
• Treatment-resistant psychotic symptoms and the 15q11.2 BP1-BP2 (Burnside-Butler) deletion syndrome: case report and review of the literature. [europepmc]
• Increasing the Clinical Psychiatric Knowledge Base About Pathogenic Copy Number Variation. [europepmc]